Liquidia CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

5 Mar 2026

LQDA

10-K: Liquidia Reports Initial YUTREPIA Sales Amidst Legal Battles

Liquidia Corporation achieved its first product sales of YUTREPIA in 2025, generating $148.3 million, but faces significant ongoing litigation and continued net losses.

NASDAQ

19 Mar 2025

LQDA

Liquidia CORP

10-K: Liquidia Corporation's 2024 10-K Filing: YUTREPIA Approval Awaits Exclusivity Expiration, Faces Ongoing Litigation

Liquidia Corporation's 2024 10-K filing highlights the company's focus on cardiopulmonary diseases, the anticipated launch of YUTREPIA pending regulatory exclusivity, and ongoing legal challenges.

NASDAQ

13 Mar 2024

LQDA

Liquidia CORP

10-K: Liquidia Corporation Outlines Financials, Pipeline and Legal Matters in 10-K Filing

Liquidia Corporation's 10-K filing details its financial status, product pipeline, ongoing litigation, and strategic agreements.